A new vaccine that protects against a respiratory virus could potentially save thousands of lives, particularly among the elderly population in the UK, a recent study suggests. Researchers at the University of Aberdeen and the MRC-University of Glasgow Centre for Virus Research conducted a review highlighting the potential impact of the respiratory syncytial virus (RSV) jab, which is now being offered to individuals aged 75 and above, as well as to women from 28 weeks of pregnancy onwards to safeguard both themselves and their infants.
Respiratory syncytial virus (RSV) commonly causes lung and respiratory tract infections, with symptoms resembling a cold in healthy adults and older children. However, it poses a severe risk to babies, older individuals, premature infants, those with heart and lung conditions, and individuals with weakened immune systems. The study, published in Age & Ageing, indicates that achieving a 70% uptake of the vaccine among the elderly demographic could prevent up to 2,800 deaths annually, along with reducing the strain on healthcare resources by saving 36,000 GP appointments, preventing 4,600 hospital admissions, and averting 1,000 intensive care unit admissions.
Professor Roy Soiza, the lead researcher from the University of Aberdeen, emphasised the importance of alleviating the healthcare burden caused by preventable infectious diseases like RSV, especially in the face of the NHS’s current challenges. The RSV vaccination programme was initiated in Scotland in August and subsequently in England, Wales, and Northern Ireland in September. Additionally, a catch-up initiative is targeting individuals aged 75 to 79 to ensure their protection before the winter season.
Despite concerns about potential vaccine hesitancy, particularly among men and those from less affluent backgrounds, data from Scotland revealed that older individuals were less likely than younger adults to decline vaccination offers. Prof Soiza stressed the safety and efficacy of the vaccines, urging healthcare professionals and caregivers to promote vaccine uptake among eligible individuals. With an effectiveness rate of approximately 86% in preventing RSV-related lower respiratory tract infections during the first year post-vaccination, the study underscores the significance of vaccination in combating respiratory illnesses.
The publication of this research coincided with the rollout of flu vaccines and Covid-19 boosters in England, where millions were encouraged to schedule their vaccinations ahead of the approaching winter months. Flu jabs, slated to commence on October 3, target individuals aged 65 and over, those aged 18 to 65 in clinical risk groups, residents of long-stay care facilities, frontline social care workers, and those providing care to the elderly or disabled. Eligible recipients for the autumn Covid booster encompass adults over 65, care home residents and personnel, frontline healthcare and social care workers, and individuals with underlying health conditions like pregnant women.
Professor Antonia Ho, an infectious diseases expert from the MRC-University of Glasgow Centre for Virus Research, emphasised the significance of the new RSV vaccines in complementing existing influenza and Covid-19 vaccination efforts to safeguard vulnerable groups against serious respiratory infections. This comprehensive approach not only protects individuals but also helps alleviate the immense pressure faced by the NHS during the winter season.